SCHEMBL695771

SCHEMBL695771

Cc1cc(N2C[C@H](S(C)(=O)=O)C[C@H]2C(=O)O)n(CCc2ccccc2)n1

nearest known ligand 0.44

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
AGTR2 P50052 5/20 0.44
GRN P28799 1/20 0.36
SORT1 Q99523 1/20 0.36
SMYD3 Q9H7B4 2/20 0.36
S1PR1 P21453 1/20 0.36
S1PR5 Q9H228 1/20 0.36
GRM2 Q14416 1/20 0.34
KMT2A Q03164 1/20 0.34
KCNJ6 P48051 1/20 0.34
KCNJ5 P48544 1/20 0.34
KCNJ3 P48549 1/20 0.34
FLT1 P17948 1/20 0.34
KDR P35968 1/20 0.34
HTT P42858 1/20 0.34
SLC5A1 P13866 1/20 0.33
NPC1 O15118 1/20 0.33
ALDH1A1 P00352 1/20 0.33
RAB9A P51151 1/20 0.33
RIPK1 Q13546 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL696202 0.91 AGTR2 (0.53) AGTR2GRNSORT1SMYD3S1PR1
SCHEMBL696201 0.91 AGTR2 (0.53) AGTR2GRNSORT1SMYD3S1PR1
SCHEMBL695636 0.91 AGTR2 (0.38) AGTR2GRNSORT1SMYD3NPC1
SCHEMBL2106353 0.91 AGTR2 (0.38) AGTR2GRNSORT1SMYD3NPC1
SCHEMBL695527 0.88 CTSS (0.47) AGTR2GRNSORT1
SCHEMBL696053 0.88 AGTR2 (0.41) AGTR2GRNSORT1SMYD3S1PR1
SCHEMBL694921 0.84 CTSS (0.51) AGTR2
SCHEMBL694977 0.84 CTSS (0.51) AGTR2
SCHEMBL694920 0.84 CTSS (0.51) AGTR2
SCHEMBL696451 0.84 CTSS (0.46)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2421826-B1 PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS HOFFMANN LA ROCHE (CH) 2013-10-23 EP claimed
US-20100267722-A1 NOVEL PROLINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-10-21 US claimed
EP-2421826-B1 PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS HOFFMANN LA ROCHE (CH) 2013-10-23 EP disclosed
US-8163793-B2 Proline derivatives HOFFMAN-LA ROCHE INC. (US) 2012-04-24 US disclosed
EP-2421826-A1 PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS F. Hoffmann-La Roche AG (CH) 2012-02-29 EP disclosed
WO-2010121918-A1 PROLINE DERIVATIVES AS CATHEPSIN INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2010-10-28 WO disclosed
US-20100267722-A1 NOVEL PROLINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2010-10-21 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267722-A1 NOVEL PROLINE DERIVATIVES PRAP1, PRR12, SLC6A7 AGTR2 317/4885GRN 836/4885SORT1 3558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.